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A B S T R A C TObjectives: Radical cystectomy (RC) is the standard treatment for
muscle-invasive urothelial carcinoma of the bladder. Trimodality
bladder-preserving therapy (BPT) is an alternative to RC, but random-
ized comparisons of RC versus BPT have proven infeasible. To
compare RC versus BPT, we undertook an observational cohort study
using registry and administrative claims data from the Surveillance,
Epidemiology and End Results-Medicare database. Methods: We
identified patients age 65 years or older diagnosed between 1995
and 2005 who received RC (n ¼ 1426) or BPT (n ¼ 417). We examined
confounding and stage misclassification in the comparison of RC and
BPT by using multivariable adjustment, propensity score–based
adjustment, instrumental variable (IV) analysis, and simulations.
Results: Patients who received BPT were older and more likely to
have comorbid disease. After propensity score adjustment, BPT was
associated with an increased hazard of death from any cause (hazard
ratio [HR] 1.26; 95% confidence interval [CI] 1.05–1.53) and fromsee front matter Copyright & 2013, International
r Inc.
.1016/j.jval.2013.01.005
t at the American Society for Radiation Oncology
n@uphs.upenn.edu.
ondence to: Justin E. Bekelman, Department of Ra
011.bladder cancer (HR 1.31; 95% CI 0.97–1.77). Using the local area
cystectomy rate as an instrument, IV analysis demonstrated no
differences in survival between BPT and RC (death from any cause
HR 1.06; 95% CI 0.78–1.31; death from bladder cancer HR 0.94; 95% CI
0.55–1.18). Simulation studies for stage misclassification yielded
results consistent with the IV analysis. Conclusions: Survival esti-
mates in an observational cohort of patients who underwent RC
versus BPT differ by analytic method. Multivariable and propensity
score adjustment revealed greater mortality associated with BPT
relative to RC, while IV analysis and simulation studies suggest that
the two treatments are associated with similar survival outcomes.
Keywords: chemotherapy, comparative effectiveness research,
cystectomy, radiotherapy, SEER Program, urinary bladder neoplasms.
Copyright & 2013, International Society for Pharmacoeconomics and
Outcomes Research (ISPOR). Published by Elsevier Inc.Introduction
Urothelial carcinoma of the bladder (UCB) affects more than 70,000
people annually in the United States, the majority of whom are
elderly, and accounts for nearly 5% of the total cost of cancer care
to Medicare. A substantial portion of patients present with or
progress to muscle-invasive UCB, an aggressive cancer associated
with a high risk of death from metastatic disease.
Radical cystectomy (RC) is the guideline-recommended stand-
ard treatment for muscle-invasive UCB and involves removal of
the bladder and prostate for men and anterior exenteration(including the bladder, uterus, ovaries, and part of the vagina)
for women. Bladder-preserving therapy (BPT), a curative treat-
ment regimen composed of transurethral resection (TUR) of the
bladder tumor, radiotherapy, and chemotherapy, presents a
compelling alternative to RC because long-term studies have
shown that the majority of BPT patients retain good bladder
function [1,2]. Yet, concerns about reduced survival without
radical surgery remain and randomized comparisons of RC to
BPT have proven infeasible.
Nonrandomized studies of RC versus BPT suffer from two
sources of bias that threaten validity in observational cancerSociety for Pharmacoeconomics and Outcomes Research (ISPOR).
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classification. Confounding occurs when measured or unmeas-
ured differences between patients are related to both the
exposure (e.g., treatment assignment) and outcome in a way that
creates a false association; for example, patients receiving cys-
tectomy tend to be younger, have fewer comorbidities, and have
better performance status. Cancer registry data sets, often used
for observational cancer CER, capture variables for patient age
and comorbidities, but do not report performance status, an
important unmeasured confounder.
Adjustment for measured confounding depends on the ability
to accurately observe possible confounding variables. Cancer
registry data sets may mischaracterize important confounding
variables; controlling for such variables may exacerbate rather
than reduce bias. For patients with UCB, those who undergo RC
have pathologic staging while those who undergo BPT have
clinical staging. Clinical stage is based on available information
obtained prior to cystectomy, including bimanual physical exami-
nation, imaging, and cystoscopy. Pathologic staging adds addi-
tional information obtained frommicroscopic examination of the
bladder specimen after cystectomy. Discordance between clinical
and pathological stage induces bias in the comparison of RC to
BPT because clinical staging is more likely to underestimate
muscle invasion, a pathologic finding that is associated with
worse survival outcomes [3].
We conducted this study to evaluate differences in survival in
the comparison of RC to BPT using traditional multivariable
regression and propensity score adjustment, which adjust for
measured confounding, and instrumental variable (IV) analyses,
which theoretically account for both measured and unmeasured
confounding. Our secondary aim was to examine the sensitivity
of traditional regression survival estimates to stage misclassifi-
cation through simulation.Methods
Study Design
The study was a retrospective, observational cohort study using
registry and administrative claims data from the Surveillance,
Epidemiology and End Results (SEER)-Medicare database. This
research was approved by the institutional review board.
Data Sources
The SEER-Medicare database links patient demographic and
tumor-specific data collected by SEER cancer registries to Medi-
care claims for inpatient and outpatient care. To obtain informa-
tion on physicians and hospitals, Medicare claims were merged
with the Medicare Physician Identification and Eligibility Record
and the SEER-Medicare hospital file. To explore candidate instru-
ments, we grouped patients into hospital referral regions (HRRs)
defined by the Dartmouth Atlas of Health Care. HRRs represent
regional health care markets for tertiary medical care.
Study Population
We identified 54,402 patients with UCB age 65 years or older
diagnosed between January 1, 1995, and December 31, 2005, in
SEER with follow-up through December 31, 2008, in Medicare. To
assign patients to therapy during the 6-month period after
diagnosis, we excluded 12,801 patients enrolled in a health
maintenance organization and 2,890 patients not enrolled in
the fee-for-service Part B Medicare program (health care claims
may not be submitted for such patients). We identified 6,486
patients with muscle-invasive (stages 2 and 3) UCB afterexcluding patients who were not staged (n ¼ 2,866), stage 0
(19,206), stage 1 (8,796), and stage 4 (1,357).
To define the primary analytic cohort eligible for either RC or
BPT, we made the following additional exclusions: RC with
chemotherapy or radiotherapy (401), radiotherapy with
non–platinum-based chemotherapy (166), palliative treatment
with chemotherapy alone, radiotherapy alone, or expectant
management (combined 3843), nonconcurrent chemoradiother-
apy (e.g., administered4 3 months apart, 54), absent Medicare
codes for initial TUR (64), HRRs with 10 or fewer patients over the
study period (50), and unknown race [2]. To avoid survivorship
bias, we excluded patients who died within 3 months of diag-
nosis (n ¼ 71; RC is associated with perioperative mortality while
BPT required that patients ‘‘survive’’ to receive trimodality ther-
apy). The primary analytic cohort was composed of 1426 RC and
417 BPT patients.
Definition of Variables
RC and BPT were assigned on the basis of identification from
Medicare inpatient, outpatient, and physician/supplier compo-
nent files using International Classification of Diseases, Ninth Revision
and Common Procedure Terminology/Healthcare Common Pro-
cedure Coding System (CPT/HCPCS) [4–6]. RC was defined as
complete cystectomy with or without pelvic lymph node dis-
section or pelvic exenteration. BPT was defined as consisting of
TUR of the bladder tumor, concurrent platinum-based chemo-
therapy, and radiotherapy.
Patient characteristics included age, gender, race, ethnicity,
marital status, tumor grade, and comorbid disease. Comorbidities
were identified by classifying all available inpatient and out-
patient Medicare claims for the 12-month interval preceding UCB
diagnosis into 46 categories [7]. We staged patients’ cancer
according to American Joint Committee on Cancer Staging
Manual, 6th edition, using SEER variables for disease extent. SEER
registries collect pathologic staging for RC patients and clinical
staging for nonsurgical patients. Physician and hospital charac-
teristics served as proxies for volume, experience, and practice
style. Physician characteristics included years in practice (from
medical school graduation), and hospital characteristics included
number of beds and academic affiliation. Patients were assigned
to urologists and hospitals on the basis of identifiers associated
with TUR billing claims. Contextual variables included year of
diagnosis, registry, population of county of residence, and
median household income in census tract of residence (US $,
obtained from the Patient Entitlement and Diagnosis Summary
File provided with SEER-Medicare data).
The primary outcomes were time to death from any cause and
time to death from bladder cancer. Underlying cause of death
was determined from SEER records. The observation time for
follow-up was calculated as the time from either cystectomy or
the start date of radio- or chemotherapy until the Medicare date
of death or end of follow-up (December 31, 2008). In the analysis
of death from bladder cancer, patients who died from a cause
other than bladder cancer were also censored at the Medicare
date of death.
Statistical Analysis
We assessed covariate imbalances between treatment groups by
using chi-square statistics and t tests. The Kaplan-Meier method
was used to compare estimates of unadjusted overall survival
and bladder cancer–specific survival. For multivariable adjust-
ment, patient, demographic, and physician/hospital variables
were included in the multivariable model, except for tumor stage
[8]. We excluded stage from our primary analyses of confounding
in multivariable, propensity score, and IV models and addressed
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simulation studies.
For propensity score adjustment, we calculated propensity
scores by using multivariable logistic regression with receipt of
RC as the outcome of interest, adjusting for patient, demo-
graphic, and physician/hospital characteristics. We used
Cochran-Mantel-Haenszel tests to determine whether covariates
were balanced within propensity score quintiles and found that
all covariates were balanced (Table 1). In propensity score models,
we adjusted for propensity score as a continuous variable [9]. In
secondary propensity score–based models, we used inverse
probability-weighted estimation [10].
We constructed multivariable Cox proportional hazard
models to compare death from any cause and from bladder
cancer between RC and BPT, accounting for within-hospital
correlation by using robust variance estimates [11]. Missing or
unknown values were entered into models as dummy variables
of a separate category [12]. The proportion missing among the
six variables with any missing data was minor (o5%). To assess
the proportional hazards assumption, we evaluated the
Schoenfeld residuals test and complementary log plots and
found that the proportional hazards assumption was violated
in some models [13]. Therefore, we examined the sensitivity
of our results to violations of proportionality by repeating
the analysis by using Weibull Accelerated Failure Time
models, which do not require the assumption of proportional
hazards [14].
IV Analysis
We formulated the IV as the local area cystectomy rate. The
instrument was created by using the entire cohort of patients
with stages 1 to 4 UCB who were potentially eligible for surgical
intervention (n ¼ 16,639), after excluding geographically
smaller HRRs with 10 or fewer patients (n ¼ 306). We assigned
patients to HRRs on the basis of their zip code at diagnosis, and
calculated the local area cystectomy rate over the 11-year study
period by dividing the number of patients who received RC by
the total number of cohort patients in the HRR. Cystectomy
rates did not change significantly over the study period. To
limit the possibility that a patient’s treatment decision would
inform his or her assigned instrument, we excluded each
patient from the calculation of his or her own instrument.
Therefore, the instrument was defined as the proportion of all
other patients (stages 1–4) in an individual’s HRR who
received RC.
The local area cystectomy rate is a strong instrument for
several reasons. First, it captures regionally distinct structural
variation in care driven by factors beyond patient characteristics,
including variation in urologist workforce supply, physician geo-
graphic distribution, and physician practice patterns [4]. Second,
it varies across HRRs and is strongly associated with treatment
assignment in the primary analytic cohort (F statistic ¼ 34.9,
where valueso 10 are considered weaker instruments) [15].
Third, it balanced prognostically important observed covariates
when the primary analytic cohort was split above and below the
median cystectomy rate (Table 2). Balance in average patient
characteristics across the IV offers reasonable evidence to infer
that the IV is not systematically related to unmeasured con-
founding variables.
We explored four other candidate instruments (urologist or
radiation oncologist density, distance to nearest hospital or
radiation facility, and urologist prior treatment preference);
however, these instruments were weak (F statistic o 10). A fifth
candidate instrument (urologist prior treatment preference) was
infeasible in this cohort because a large portion of urologists
treated fewer than 5 patients.We used the two-stage residual inclusion method for IV
estimation [16]. Standard errors were obtained via bootstrapping
with bias correction [17].
Simulation for Stage Misclassification
Because prognostically important discrepancies have been
reported between pathologic and clinical staging for UCB, sur-
vival outcomes of BPT will appear worse than those of RC if
adjusted for SEER tumor stage as a result of misclassification
error. This discordance also makes stage endogenous to the IV; as
recorded by SEER, stage is associated with both treatment assign-
ment and survival.
To examine the sensitivity of traditional regression survival
estimates to stage misclassification, we evaluated what affect
pathologic up- and down-staging of BPT patients would have on
the hazard ratio (HR) estimates of the association between BPT
and survival, based on multivariable models adjusted for meas-
ured covariates and SEER stage. Table 3 presents multivariable
models without and with adjustment for stage. We estimated the
plausible range of stage misclassification on the basis of a large,
multiinstitutional cohort of patients who underwent clinical
staging by TUR and subsequent pathologic staging by RC (53.5%
of clinical stage 2 patients were up-staged to pathologic stage 3
and 20.5% of clinical stage 3 patients were down-staged to
pathologic stage 2) [3]. We developed12 scenarios in which we
varied the proportion of BPT patients up-staged (35%, 45%, 55%,
and 65% of stage 2 BPT patients) and down-staged (10%, 20%, and
30% of stage 3 BPT patients). In each scenario, we simulated 250
data sets in which the designated proportions of BPT patients
were randomly up-staged or down-staged.
Statistical modeling and simulation studies were performed
by using SAS version 9.2 (Cary, NC) and R version 2.13.0 (Vienna,
Austria).Results
Table 1 presents selected baseline characteristics of the 1426
patients who received RC and the 417 patients who received BPT.
Patients who received BPTwere older, more likely to be male, and
more likely to have a history of cardiac arrhythmia, perivascular
disease, congestive heart failure, or valvular disease.
Table 2 compares patients groups by whether the local area
cystectomy rate was below or above the median rate. Prognosti-
cally important covariates (i.e., age, history of comorbid disease)
were well balanced. The most prominent characteristic not bal-
anced was race.
Figure 1 shows unadjusted Kaplan-Meier plots for survival in
the two treatment groups. Unadjusted 5-year overall survival was
46.5% in the RC group versus 27.9% in the BPT group and 5-year
bladder cancer–specific survival was 64.5% in the RC group versus
52.2% in the BPT group.
Table 4 presents HRs associated with BPT relative to RC from
univariate, multivariable, propensity score, and IV analysis. In
unadjusted Cox models, BPTwas associated with increased death
from any cause (HR 1.54; 95% confidence interval [CI] 1.33–1.77)
and from bladder cancer (HR 1.42; 95% CI 1.17–1.73). After
adjusting for measured confounders using multivariable and
propensity score–based methods, BPT remained associated with
increased rate of death from any cause (propensity
score–adjusted HR 1.26; 95% CI 1.05–1.53) and from bladder
cancer (propensity score–adjusted HR 1.31; 95% CI 0.97–1.77). IV
analysis produced substantially attenuated survival estimates of
BPT versus RC (HR for death from any cause 1.06; 95% CI
0.78–1.31; HR for death from bladder cancer 0.94; 95% CI
0.55–1.18). Parallel estimation of hazards by using Accelerated
Table 1 – Distribution of characteristics across treatment groups before and after propensity score adjustment.
n (%) P
Radical
cystecomy
Bladder- preserving
therapy
Before
adjustment
After propensity
adjustment
All patients 1426 (77.4) 417 (22.6)
Patient characteristics
Age at diagnosis (y), mean  SD 75.4  6.2 79.3  6.0 o0.001 0.21
Gender
Male 892 (62.6) 300 (71.9)
Female 534 (37.4) 117 (28.1) o0.001 0.76
Race
White 1308 (91.7) 392 (94.0) 0.07 0.91
Marital status
Married 860 (60.3) 233 (55.9)
Not married 525 (36.8) 171 (41.0) 0.27 0.97
Tumor grade
Moderately differentiated 92 (6.5) 27 (6.5)
Poorly differentiated 1309 (91.8) 376 (90.2) 0.16 0.97
Comorbidities
Hypertension 920 (64.5) 285 (68.3) 0.15 0.93
Chronic obstructive pulmonary disease 407 (28.5) 117 (28.1) 0.85 0.85
Arrythmia 311 (21.8) 123 (29.5) 0.001 0.81
Anemia 320 (22.4) 95 (22.8) 0.88 0.97
Perivascular disease 265 (18.6) 109 (26.1) o0.001 0.70
Diabetes 277 (19.4) 83 (19.9) 0.83 0.96
Hypothyroidism 216 (15.1) 67 (16.1) 0.65 0.96
Congestive heart failure 155 (10.9) 76 (18.2) o0.001 0.49
Valvular disease 159 (11.2) 65 (15.6) 0.01 0.93
Electrolyte abnormality 132 (9.3) 47 (11.3) 0.22 0.94
Other comorbidity 390 (27.3) 132 (31.7) 0.09 0.94
Demographic characteristics
Population of county of residence
1,000,000 or more 783 (54.9) 222 (53.2)
250,000–999,999 294 (20.6) 91 (21.8)
0–249,999 349 (24.5) 104 (24.9) 0.81 0.91
Median household income in census tract of
residence (US $)
25,000 or less 165 (11.6) 31 (7.4)
425,000–40,000 477 (33.5) 121 (29.0)
440,000–60,000 463 (32.5) 170 (40.8)
460,000 310 (21.7) 91 (21.8) 0.008 0.99
Hospital and physician characteristics
Hospital academic affiliation 749 (52.5) 209 (50.1) 0.69 0.99
Hospital beds
r148 356 (25.0) 93 (22.3)
149–238 344 (24.1) 103 (24.7)
239–342 329 (23.1) 117 (28.1)
Z343 357 (25.0) 85 (20.4)
Unknown 40 (2.8) 19 (4.6) 0.04 0.99
Physician practice years
r16 337 (23.6) 111 (26.6)
417–24 365 (25.6) 88 (21.1)
424–33 373 (26.2) 113 (27.1)
433 307 (21.5) 103 (24.7) 0.007 0.98
Note. During the study period, information on incident cancer cases was available from 16 cancer registries covering approximately 26% of the
US population. The Greater California, Kentucky, Louisiana, and New Jersey case contributions began in 2000. The highest RC rate was in San
Francisco and the highest BPT rate was in Iowa. Diagnosis year and registry covariates were balanced after propensity score adjustment (data
not shown). Selected race, ethnicity, marital, status, grade, and physician practice cells suppressed according to SEER-Medicare guidelines for
reporting cell sizes o 11 patients. Ethnicity was balanced after propensity score adjustment (data not shown).
BPT, bladder-preserving therapy; RC, radical cystectomy; SEER, Surveillance, Epidemiology and End Results.
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Table 2 – Distribution of characteristics across cohorts grouped by median value of instrument.
n (%)
Below median IV Above median IV P
All patients 918 (49.8) 925 (50.2)
Median survival (y, 95% CI) 3.7 (3.1–4.2) 3.4 (2.9–3.9) 0.71y
Treatment
Radical cystectomy 675 (73.5) 751 (81.2)
Bladder-preserving therapy 243 (26.5) 174 (18.8) o0.001
Patient characteristics
Age at diagnosis (y), mean  SD 76.5  6.4 76.1  6.4 0.17
Gender
Male 590 (64.3) 602 (65.1)
Female 328 (35.7) 323 (34.9) 0.72
Race
White 851 (92.7) 849 (91.8) o0.001
Marital status
Married 548 (50.1) 545 (49.9)
Not married 335 (48.1) 361 (51.9) 0.06
Tumor grade
Moderately differentiated 57 (6.2) 62 (6.7)
Poorly differentiated 836 (91.0) 849 (91.8) 0.29
Comorbidities
Hypertension 589 (64.2) 616 (66.6) 0.27
Chronic obstructive pulmonary disease 254 (27.7) 270 (29.2) 0.47
Arrythmia 224 (24.4) 210 (22.7) 0.39
Anemia 209 (22.8) 206 (22.3) 0.80
Perivascular disease 187 (20.4) 187 (20.2) 0.93
Diabetes 170 (18.5) 190 (20.5) 0.27
Hypothyroidism 130 (14.2) 153 (16.5) 0.16
Congestive heart failure 119 (13.0) 112 (12.1) 0.58
Valvular disease 124 (13.5) 100 (10.8) 0.08
Electrolyte abnormality 96 (10.5) 83 (9.0) 0.28
Other comorbidity 265 (28.9) 257 (27.8) 0.61
Demographic characteristics
Population of county of residence
1,000,000 or more 512 (55.8) 493 (53.3)
250,000–999,999 174 (19.0) 211 (22.8)
0–249,999 232 (25.3) 221 (23.9) 0.13
Median household income in census tract of residence (US $)
25,000 or less 89 (9.7) 107 (11.6)
425,000–40,000 273 (29.7) 325 (35.1)
440,000–60,000 328 (35.7) 305 (33.0)
460,000 221 (24.1) 180 (19.5) 0.02
Hospital and physician characteristics
Hospital academic affiliation 505 (55.0) 453 (49.0) 0.03
Hospital beds
r148 202 (45.0) 247 (55.0)
149–238 217 (48.5) 230 (51.5)
239–342 241 (54.0) 205 (46.0)
Z343 230 (52.0) 212 (48.0)
Unknown 28 (47.5) 31 (52.5) 0.07
Physician practice years
r16 223 (49.8) 225 (50.2)
417–24 225 (49.7) 228 (50.3)
424–33 262 (53.9) 224 (46.1)
433 189 (46.1) 221 (53.9)
Unknown 19 (41.3) 27 (58.7) 0.14
CI, confidence interval; IV, instrumental variable; SEER, Surveillance, Epidemiology and End Results.
Selected race, ethnicity, marital status, and grade cells suppressed according to SEER-Medicare guidelines for reporting cell sizes o11 patients.
Ethnicity, like race, was not balanced across levels of IV (data not shown). Diagnosis year was balanced across levels of IV (data not shown).
y Log-rank P value.
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Table 3 – Significant covariates associated with death from any cause or from bladder cancer after
multivariable model risk adjustment (Cox proportional hazards regression).
HR (95% CI) P Value
Multivariable model adjusted for covariates
without stage
Multivariable model adjusted for covariates
with stage
Death from any
cause
Death from bladder
cancer
Death from any
cause
Death from bladder
cancer
BPT, relative to RC 1.26 (1.07–1.50) 0.006 1.28 (0.98–1.68) 0.068 1.42 (1.21–1.67) o0.001 1.53 (1.16–2.02) 0.003
Stage III, relative to II – – 1.65 (1.46– 1.85)o0.001 1.98 (1.75–2.24)o0.001
Age (each additional year) 1.04 (1.03–1.05)o0.001 1.03 (1.01– 1.04) o0.001 1.04 (1.03– 1.05)o0.001 1.03 (1.01–1.04)o0.001
Female, relative to male 0.91 (0.80–1.03) 0.13 1.26 (1.06–1.49) 0.009 0.91 (0.80–1.05) 0.201 1.27 (1.05–1.54) 0.015
Not married, relative to
married
1.14 (1.03–1.27) 0.015 1.02 (0.89–1.18) 0.752 1.14 (1.02–1.28) 0.021 1.01 (0.87–1.17) 0.92
Comorbid disease
Hypertension, relative to
none
1.17 (1.03–1.32) 0.018 1.18 (1.02–1.37) 0.029 1.15 (1.00–1.31) 0.048 1.16 (0.99–1.35) 0.065
COPD, relative to none 1.21 (1.05–1.40) 0.009 1.06 (0.88–1.27) 0.53 1.22 (1.06–1.41) 0.006 1.07 (0.89–1.28) 0.46
Anemia 1.15 (1.02–1.31) 0.027 1.12 (0.95–1.31) 0.17 1.15 (1.02–1.31) 0.028 1.13 (0.96–1.33) 0.14
Perivascular, relative to
none
1.10 (0.97–1.25) 0.127 1.11 (0.94–1.31) 0.21 1.13 (1.01–1.28) 0.040 1.15 (0.98–1.34) 0.08
CHF, relative to none 1.29 (1.09–1.52) 0.002 1.25 (1.00–1.56) 0.047 1.28 (1.08–1.53) 0.005 1.26 (0.99–1.59) 0.059
Electrolyte abnormality,
relative to none
1.25 (1.08–1.44) 0.003 1.14 (0.89–1.45) 0.29 1.23 (1.06–1.43) 0.008 1.09 (0.86–1.39) 0.48
Other comorbidity, relative
to no other
1.27 (1.13–1.41)o0.001 1.32 (1.13–1.54)o0.001 1.22 (1.09–1.37) 0.001 1.27 (1.08–1.49) 0.003
CI, confidence interval; BPT, bladder-preserving therapy; CHF, congestive heart failure; COPD, chronic obstructive pulmonary disease; HR,
hazard ratio; RC, radical cystectomy; SEER, Surveillance, Epidemiology and End Results.
 Adjusted for age, race, ethnicity, marital status, tumor grade, comorbidity, diagnosis year, SEER registry, area population, median income,
physician practice years, hospital beds, and hospital academic affiliation.
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significance with Cox models (Table 4).
Simulation studies for 12 scenarios of stage misclassification
are presented in Figure 2 and are based on the multivariable HR
for death from any cause for BPT versus RC, adjusted for all
covariates and SEER stage (HR 1.42; 95% CI 1.21–1.67). Stage 3 was
reported in 41% of RC and 16% of BPT patients, though SEERMonths
0
No. at risk
RC            1,426            808      508      302      125        64        21       0
BPT             417            174        85       46        14        <11 <11       
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Fig. 1 – Unadjusted Kaplan-Meier estimates of the proportion s
according to SEER-Medicare reporting guidelines. BPT, bladder-
Surveillance, Epidemiology and End Results.reports pathologic stage for RC patients and clinical stage for BPT
patients. Not surprisingly, the HR estimate adjusted for all
covariates and SEER stage is increased in comparison to esti-
mates from adjusted models without SEER stage (Table 3).
In 250 simulated data sets in which 55% of the BPT patients
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staging consistent with prior evidence [3] for pathologicMonths
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Table 4 – Unadjusted and adjusted hazard ratios associated with BPT relative to RC.
HR (95% CI)
Cox proportional hazards regression Accelerated failure time model
Death from any
cause
Death from bladder
cancer
Death from any
cause
Death from bladder
cancer
Unadjusted model 1.54 (1.33–1.77) 1.42 (1.17–1.73) 1.75 (1.51–2.03) 2.27 (1.65–3.11)
Multivariable model 1.26 (1.07–1.50) 1.28 (0.98–1.68) 1.33 (1.15–1.53) 1.66 (1.21–2.27)
Propensity score model 1.26 (1.05–1.53) 1.31 (0.97–1.77) 1.36 (1.16–1.59) 1.79 (1.27–2.51)
Inverse probability-
weighted
1.27 (1.06–1.53) 1.34 (1.02–1.77) 1.39 (1.26–1.53) 1.88 (1.55–2.27)
IV model 1.06 (0.78–1.31) 0.94 (0.55–1.18) 1.13 (0.77–1.47) 1.02 (0.34–1.52)
Note. The hazard ratio (HR) is an estimate of the hazard of death in the BPT group versus the RC group. A hazard ratio of41 indicates worse
survival in the BPT group. Multivariable and propensity score models adjusted for all covariates except the SEER stage. The IV model adjusted
for all covariates except SEER registry and SEER tumor stage (e.g., tumor stage was excluded from the IV analysis because it was endogenous to
the instrument; as clinical and pathologic stage is recorded by SEER in a single variable, stage is associated with treatment and outcomes).
BPT, bladder-preserving therapy; CI, confidence interval; IV, instrumental variable; RC, radical cystectomy; SEER, Surveillance, Epidemiology
and End Results.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 6 1 0 – 6 1 8616understaging at TUR), we no longer observed a significant differ-
ence in mortality between BPT and RC in any simulations based
on traditional multivariable regression (e.g., the lower bound of
the 95% CI crossed 1), regardless of the proportion of BPT patients
randomly down-staged (Fig. 2, panels C, G, and K). Simulations
for the influence of stage misclassification on the HR for death
from bladder cancer were consistent with simulations for death
from any cause (data not shown).Discussion
The comparison of survival outcomes after surgical versus organ-
preserving treatment for muscle-invasive UCB illustrates the
particular challenges of uncontrolled confounding and variable
misclassification in observational cancer CER. In this registry
cohort, treatment assignment is influenced by severe selection
effects and outcomes are vulnerable to systematic misclassifica-
tion of tumor stage.
We observed differences in mortality estimates derived from
traditional regression models (that adjust only for measured
confounding) and IV models (that theoretically adjust for both
measured and unmeasured confounding). Traditional multivari-
able or propensity score methods attenuated the unadjusted
association between BPT and increased mortality, whereas the
IV analysis demonstrated no survival difference between
treatments.
Why might traditional regression methods reveal mortality
differences between RC and BPT? One explanation may be that
surgical resection of tumor is a critical component of curative
therapy and leads to better survival outcomes compared with
bladder preservation [18]. An alternative explanation, however, is
that residual unmeasured bias remains in the comparison of RC
to BPT. Patients treated with BPT in this cohort were older and
more likely to have congestive heart failure, arrhythmias, and
perivascular disease, which is consistent with confounding by
indication. The severity of comorbidity in the BPT group, how-
ever, is not available from SEER-Medicare data, nor are other
important unmeasured confounders, such as performance status
or cognitive impairment. Traditional regression methods may
yield effect estimates that are biased upwards because of uncon-
trolled confounding. Moreover, traditional regression may intro-
duce bias when important measured confounders, such as tumor
stage, are misclassified.Can IV analyses be relied upon to disentangle the degree of
confounding present in the comparison of RC to BPT? While the
instrument theoretically balanced unmeasured variables
between patient groups, this relies on the unverifiable assump-
tion that the instrument is not systematically related to unmeas-
ured confounding variables. It is possible, for example, that
patients living in high cystectomy areas also have greater access
to health care in general. IV methods may yield effect estimates
that are biased downwards if unmeasured correlates of survival,
such as access to health care, are associated with the instru-
ment. We mitigated this risk by also adjusting for neighborhood
socioeconomic status (though associations with unmeasured
confounding variables may remain). Moreover, the results of
the IV analysis have external validity; BPT efficacy trials, which
have included patients with T2 to T4a disease, have achieved
survival rates comparable to those reported in contemporary
cystectomy series [2,19]. Ultimately, the degree to which IV
analyses should be relied upon in any particular comparison
depends largely on the degree to which the underlying assump-
tions are believed.
Beyond possible differences in confounding control, the two
analytic techniques produce effect estimates that apply to differ-
ent patient populations. Traditional regression estimates average
treatment effects for a population of patients, while IV methods
apply to the set of ‘‘marginal patients’’ whose treatment choice
depends on the instrument—in this case, to those patients who
would be treated in high cystectomy areas but not in low
cystectomy areas [20]. Previous research has shown that radical
cystectomy is underused, particularly among older patients,
those with greater comorbidities, and those who live far from
cystectomy-performing hospitals; such patients could be affected
by a cystectomy rate increase [4]. Our IV results suggest that
survival outcomes after RC versus BPT among these patients may
be similar (provided they are candidates for either treatment).
When tumor stage was incorporated into traditional multivari-
able survival models, the relative mortality difference between BPT
and RC increased in comparison to multivariable models without
stage. Prognostically important discordance between clinical and
pathologic staging has been shown for lung and prostate cancer and
affects the interpretation of studies that compare radical surgery to
alternative treatments without a primary resectional component
[21,22]. In bladder cancer, survival outcomes of BPT appear worse if
adjusted for SEER tumor stage because of systematic stage mis-
classification. In sensitivity analyses for stage misclassification,
Fig. 2 – Effect of pathologic up-staging and down-staging of BPT patients on the hazard ratio of death from any cause
adjusted for covariates and tumor stage. Note. Each of 12 panels depicts 250 simulated data sets in which BPT patients were
randomly up-staged or down-staged at proportions consistent with pathologic under- and overstaging at TUR. Black
diamonds depict the HR point estimate, and gray vertical bars depict 95% confidence interval (CI). Black line denotes when
the lower bound of the 95% CI crosses 1. The estimated HR for death from any cause for BPT versus RC, adjusted for all
covariates and tumor stage, was 1.42 (95% CI 1.21–1.67). As shown in panel B, where 45% of the BPT patients were up-staged
from stage 2 to stage 3 and 10% of the BPT patients were down-staged from stage 3 to stage 2, we no longer observed a
statistically significant difference in death from any cause between BPT and RC in 88% of the simulations. When 55% of the
BPT patients with stage 2 were up-staged, we no longer observed a statistically significant difference between BPT and RC in
any of the simulations. HR, hazard ratio; TUR, transurethral resection.
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 6 1 0 – 6 1 8 617mortality differences between RC and BPTwere no longer significant
under plausible scenarios of pathologic up-staging and down-
staging. Notably, the results of the simulation studies were direc-
tionally consistent with the results of the IV analyses.
Our results extend the work of previous studies that have
examined alternative treatments for muscle-invasive UCB. These
studies found that RC extended survival relative to radiation and/
or chemotherapy or no further treatment [4,5]. In contrast, we
attempted to mimic the design of a randomized trial of two
curative approaches for muscle-invasive UCB by comparing RC to
BPT, a treatment alternative with curative intent that involves a
specific regimen of trimodality therapy. Differences in survival
estimates between our work and that of others underscore how
important the choice of the ‘‘comparator’’ is to both observational
CER and randomized trials [23].
Our study is limited in that we did not compare BPT to
neoadjuvant chemotherapy prior to RC, which may improve
survival over RC alone. We identified only a small number of
patients in SEER-Medicare data who received neoadjuvant che-
motherapy. This group, surprisingly, had worse survival outcomes
than did the RC-alone group, which possibly reflects uncertainty
about who benefits from neoadjuvant chemotherapy and selec-
tion effects among those to whom it was delivered. Including
such patients in the comparison of BPT to RC wouldinappropriately reduce the survival estimates of the RC group.
In addition, we did not adjust for hospital/provider procedure
volume because the two primary treatments under study are
performed by different physicians and different health care
facilities (i.e., RC is a hospital-based surgery, while BPT involves
outpatient radiotherapy and chemotherapy delivery).
In conclusion, we found that survival estimates in an obser-
vational cohort of patients who underwent RC versus BPT differ
by analytic method. While the results of the IV analyses and
sensitivity analyses for stage misclassification may cast doubt on
the findings of the traditional regression models, we also caution
that effect estimates from the IV models are conditional on
strong assumptions and are generalizable to those patients
whose treatment choice depends on the instrument (e.g., those
who would be affected by an increase in cystectomy rates). In
the absence of randomized trials, careful application and inter-
pretation of analytic methods to control for confounding can
provide insights into treatment effectiveness.Acknowledgments
This study used the linked Surveillance, Epidemiology, and End
Results (SEER)–Medicare database. The authors acknowledge the
VA L U E I N H E A LT H 1 6 ( 2 0 1 3 ) 6 1 0 – 6 1 8618efforts of the Applied Research Program, National Cancer Insti-
tute (NCI), the Office of Research, Development and Information,
Centers for Medicare & Medicaid Services (CMS), Information
Management Services (IMS), Inc., and the SEER Program tumor
registries in the creation of the SEER-Medicare database. We
thank Robert Sunderland, MS, for programming assistance. We
gratefully acknowledge the mentorship of Thomas Ten Have,
PhD, MPH.
Source of financial support: This study was supported by
grants from the National Institutes of Health (RC4-CA155809),
the National Cancer Institute (RC2-CA148310, K12-CA076931, and
1K07CA163616), the National Cancer Institute and the Office of
Behavioral and Social Sciences Research (1K07CA151910), the US
Public Health Service (P30-CA016520), and the Thomas B. and
Jeannette E. Laws McCabe Fund. The funding agencies did not
participate in the design and conduct of the study; in the
collection, analysis, and interpretation of the data, or in the
preparation, review, or approval of the manuscript.
R E F E R E N C E S[1] Efstathiou J, Spiegel DY, Shipley WU, et al. Long-term outcomes of
selective bladder preservation by combined-modality therapy for
invasive bladder cancer: the MGH experience. Eur Urol 2012;61:705–11.
[2] James ND, Hussain SA, Hall E, et al. Radiotherapy with or without
chemotherapy in muscle-invasive bladder cancer. N Engl J Med
2012;366:1477–88.
[3] Svatek RS, Shariat SF, Novara G, et al. Discrepancy between clinical and
pathological stage: external validation of the impact on prognosis in an
international radical cystectomy cohort. BJU Int 2011;107(6):898–904.
[4] Gore JL, Litwin MS, Lai J, et al. Use of radical cystectomy for patients
with invasive bladder cancer. J Natl Cancer Inst 2010;102:802–11.
[5] Schrag D, Mitra N, Xu F, et al. Cystectomy for muscle-invasive bladder
cancer: patterns and outcomes of care in the Medicare population.
Urology 2005;65:1118–25.
[6] Hollenbeck BK, Wei Y, Birkmeyer JD. Volume, process of care, and
operative mortality for cystectomy for bladder cancer. Urology
2007;69:871–5.[7] Elixhauser A, Steiner C, Harris D, Coffey R. Comorbidity measures for
use with administrative data. Med Care 1998;36:8–27.
[8] Homer D, Lemeshaw S. Applied Survival Analysis: Regression Modeling
of Time to Event Data. New York: John Wiley and Sons, 1999.
[9] Rubin DB, Thomas N. Matching using estimated propensity scores:
relating theory to practice. Biometrics 1996;52:249–64.
[10] Curtis LH, Hammill BG, Eisenstein EL, et al. Using inverse probability-
weighted estimators in comparative effectiveness analyses with
observational databases. Med Care 2007;45(10, Suppl. 2):S103–7.
[11] Lin DY, Wei LJ. The robust inference for the proportional hazards
model. J Am Stat Assoc 1989;84:1074–8.
[12] Rosenbaum P, Robin D. Reducing bias in observational studies using
subclassification on the propensity score. J Am Stat Assoc
1984;79:516–24.
[13] Collett D. Modelling Survival Data in Medical Research(2nd ed.). New
York, NY: Chapman and Hall/CRC, 2003.
[14] Wei L. The accelerated failure time model: a useful alternative to the
Cox regression in survival analysis. Stat Med 1992;11:1871–9.
[15] Brookhart MA, Rassen JA, Schneeweiss S. Instrumental variable
methods in comparative safety and effectiveness research.
Pharmacoepidemiol Drug Saf 2010;19:537–54.
[16] Terza JV, Basu A, Rathouz PJ. Two-stage residual inclusion estimation:
addressing endogeneity in health econometric modeling. J Health Econ
2008;27:531–43.
[17] Efron B, Tibshirani RJ. An Introduction to the Bootstrap. Boca Raton, FL:
Chapman & Hall, 1994.
[18] Simone G, Gallucci M. Multimodality treatment versus radical
cystectomy: bladder sparing at cost of life? Eur Urol 2012;61:712–4.
[19] Kaufman DS, Shipley WU, Feldman AS. Bladder cancer. Lancet
2009;374:239–49.
[20] Harris KM, Remler DK. Who is the marginal patient? Understanding
instrumental variables estimates of treatment effects. Health Serv Res
1998;33(5, Pt 1):1337–60.
[21] Stiles BM, Servais EL, Lee PC, et al. Point: Clinical stage IA non-small
cell lung cancer determined by computed tomography and positron
emission tomography is frequently not pathologic IA non-small cell
lung cancer: the problem of understaging. J Thorac Cardiovasc Surg
2009;137:13–9.
[22] Cooke E.W., Shrieve D.C., Tward J.D. Clinical versus pathologic staging
for prostate adenocarcinoma: how do they correlate? 2012;35:364–8.
[23] Chokshi DA, Avorn J, Kesselheim AS. Designing comparative
effectiveness research on prescription drugs: lessons from the clinical
trial literature. Health Aff (Millwood) 2010;29:1842–8.
